Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Cancer
Interventions: DRUG: FLX475|DRUG: Pembrolizumab
Sponsor: RAPT Therapeutics, Inc.
Collaborators: Merck Sharp & Dohme LLC